Proteostasis Therapeutics, Inc

(NASDAQ:PTI)

Latest On Proteostasis Therapeutics, Inc (PTI):

Date/Time Type Description Signal Details
2020-12-23 18:01 ESTNewsProteostasis Therapeutics completes merger with Yumanity Therapeutics, effects 1-for-20 reverse stock splitN/A
2020-12-23 04:29 ESTStock SplitA stock split has occured on Dec 23, 2020 with a split factor of 1:20.Neutral
2020-12-08 12:41 ESTAnalyst RatingThe Analyst Target Price has increased from $4.67 to $5.Buy
2020-11-26 21:17 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 04:38 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 17:29 ESTNewsProteostasis Therapeutics EPS beats by $0.02N/A
2020-11-17 12:37 ESTEarnings EstimateAn EPS average of -$0.12 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-08 00:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:54 ESTFinancialsCompany financials have been released.Neutral
2020-10-15 09:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $5 to $4.67.Neutral
2020-09-26 13:49 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:55 ESTFinancialsCompany financials have been released.Neutral
2020-08-24 11:23 ESTNewsProteostasis Therapeutics to merge with Yumanity TherapeuticsN/A
2020-08-17 09:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.5 to $5.Neutral
2020-08-14 09:53 ESTFinancialsCompany financials have been released.Neutral
2020-08-09 01:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 00:40 ESTNewsProteostasis Therapeutics EPS beats by $0.04N/A
2020-08-06 13:40 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:35 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:35 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:12 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 17:33 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 13:26 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:51 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 09:27 ESTEarnings EstimateAn EPS average of -$0.26 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-01 20:22 ESTNewsProteostasis Therapeutics' PTI-129 a potential COVID-19 candidateN/A
2020-05-28 09:24 ESTNewsProteostasis Therapeutics: A Clinical Stage Company That's Worth The RiskN/A
2020-05-27 05:59 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 01:35 ESTFinancialsCompany financials have been released.Neutral
2020-05-20 17:25 ESTFinancialsCompany financials have been released.Neutral
2020-05-16 15:50 ESTNewsProteostasis Therapeutics EPS beats by $0.07N/A
2020-05-06 06:06 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:34 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 09:11 ESTNewsProteostasis Therapeutics EPS beats by $0.06N/A
2020-04-10 01:28 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 21:34 ESTFinancialsCompany financials have been released.Neutral
2020-03-13 01:21 ESTFinancialsCompany financials have been released.Neutral
2020-03-12 05:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $5.75 to $5.5.Neutral
2020-03-11 05:21 ESTEarnings EstimateAn EPS average of -$1.29 is estimated for the 2021 year.Sell
2020-03-11 05:21 ESTEarnings EstimateAn EPS average of -$0.37 is estimated for the quarter ending on June 30, 2020.Sell
2020-02-28 04:47 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:47 ESTEarningsEarnings have been released on June 1, 2016, with -$0.87 earnings per share.Sell
2020-02-28 04:47 ESTEarningsEarnings have been released on March 27, 2019, with -$0.36 earnings per share.Buy
2020-02-27 22:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 00:31 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 00:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 00:31 ESTFinancialsCompany financials have been released.Neutral

About Proteostasis Therapeutics, Inc (PTI):

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

PTI Quotes by TradingView

See Advanced Chart

General

  • Name Proteostasis Therapeutics, Inc
  • Symbol PTI
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 44
  • Last Split Factor1:20
  • Last Split Date2020-12-23
  • Fiscal Year EndDecember
  • IPO Date2016-02-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.proteostasis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 16.26
  • Price/Book (Most Recent Quarter) 1.56
  • Enterprise Value Revenue 2.69
  • Enterprise Value EBITDA 0.03
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.18
  • Return on Assets -31%
  • Return on Equity -72%
  • Earnings Per Share -$1.50
  • Revenue Per Share $0
  • Gross Profit 5 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 2.9 million
  • EBITDA -70493000
  • Analyst Target Price $5
  • Book Value Per Share $0.71
View More

Share Statistics

  • Shares Outstanding 52.18 million
  • Shares Float 41.43 million
  • % Held by Insiders 1530%
  • % Held by Institutions 22.57%
  • Shares Short 1.09 million
  • Shares Short Prior Month 1.31 million
  • Short Ratio 2.57
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.12
  • 52 Week High $37.4
  • 52 Week Low $18.77
  • 50 Day Moving Average 2.64
  • 200 Day Moving Average 1.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Proteostasis Therapeutics, Inc (PTI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Proteostasis Therapeutics, Inc (PTI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-16$N/A-$0.11-$0.1838.61%
2020-06-302020-08-06$N/A-$0.17-$0.2120%
2020-03-312020-05-15$N/A-$0.19-$0.2625.49%
2019-12-312020-03-10$N/A-$0.23-$0.2920%
2019-09-302019-11-07$N/A-$0.25-$0.4138.53%
2019-06-302019-08-07$N/A-$0.39-$0.38-3.53%
2019-03-312019-05-08$5 million-$0.28-$0.3622.22%
2018-12-312019-03-08$1.79 million-$0.36-$0.409.25%
2018-09-302018-11-06$1.06 million-$0.50-$0.43-15.39%
2018-06-302018-08-08$843000-$0.43-$0.36-19.44%
2018-03-312018-05-09$942000-$0.32-$0.5440.38%
2017-12-312018-03-14$1.62 million-$0.50-$0.6118.03%
2017-09-302017-11-14$1.55 million-$0.56-$0.6918.84%
2017-06-302017-08-04$1.15 million-$0.68-$0.59-15.25%
2017-03-312017-05-12$1.02 million-$0.60-$0.54-11.11%
2016-12-312017-03-30$4.06 million-$0.38-$0.5023.23%
2016-09-302016-11-10$1.72 million-$0.54-$0.50-7.29%
2016-06-302016-08-15$1.45 million-$0.47-$0.6729.32%
2016-03-312016-05-13$1.16 million-$0.87-$0.51-69.49%
2015-12-312016-02-18$1.23 million-$0.58-$0.8229.27%

Proteostasis Therapeutics, Inc (PTI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 6.52 million 8.65 million 10.15 million
Income Before Tax N/A N/A -9.88 million -11.86 million -12.83 million
Selling General Administrative N/A N/A 3.59 million 3.51 million 3.15 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -9.52 million -12.16 million -13.3 million
Operating Income N/A N/A -10.11 million -12.16 million -13.3 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A 23000 300000 466000
Net Income From Continuing Operations N/A N/A -9.88 million -11.86 million -12.83 million
Net Income Applicable to Common Shares -8.17 million -8.89 million N/A -11.86 million -12.83 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A 20.77 million -1.9 million 17.15 million
Change to Liabilities -622000 303000 N/A -1.78 million 908000
Total Cash Flow from Investing Activities 1 million 17.72 million N/A -1.9 million 17.15 million
Net Borrowings -366000 -364000 N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 1.13 million 3.27 million 25000
Change to Operating Activities 363000 -331000 N/A 1.05 million 341000
Change in Cash N/A N/A 8.34 million -10.3 million 6.67 million
Total Cash from Operating Activities -7.78 million -7.84 million -13.55 million -11.67 million -10.5 million
Depreciation N/A N/A 357000 355000 355000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A -230000 N/A
Change to Net Income 604000 1.35 million N/A 558000 725000
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 19.95 million 22.35 million 23.92 million
Total Stockholder Equity N/A N/A 53.14 million 62.38 million 70.12 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A 73.09 million 84.72 million 94.04 million
Common Stock 52000 52000 N/A 52000 51000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -363.6 million -355.43 million -346.54 million -336.66 million -324.8 million
Other Liabilities 3000 3000 N/A 3000 3000
Other Assets 828000 828000 N/A 828000 940000
Cash N/A N/A 33.35 million 25.01 million 35.3 million
Total Current Liabilities 6.15 million N/A 8.2 million 10.3 million 11.57 million
Other Stockholder Equity N/A N/A N/A 7000 16000
Property, Plant & Equipment 11.95 million 12.31 million N/A 13.03 million 13.4 million
Total Current Assets 41.57 million N/A 59.59 million 70.87 million 79.69 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 37.09 million 44.94 million N/A 62.38 million 70.12 million
Short Term Investments N/A N/A 23.75 million 44.46 million 42.46 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 882000 N/A 1.2 million 2.28 million 4.07 million

Proteostasis Therapeutics, Inc (PTI) Chart:

Proteostasis Therapeutics, Inc (PTI) News:

Below you will find a list of latest news for Proteostasis Therapeutics, Inc (PTI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Proteostasis Therapeutics, Inc (PTI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Proteostasis Therapeutics, Inc (PTI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039868/0001209191-20-039868-index.htm
2018-11-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1445283/000000000018036766/0000000000-18-036766-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000005341719000060/0000053417-19-000060-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000005341720000057/0000053417-20-000057-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000021545719006898/0000215457-19-006898-index.htm
2019-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000021545719008347/0000215457-19-008347-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000090221919000232/0000902219-19-000232-index.htm
2019-11-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000090221919000468/0000902219-19-000468-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000092963819000262/0000929638-19-000262-index.htm
2018-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000093041318003265/0000930413-18-003265-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000093041319000561/0000930413-19-000561-index.htm
2019-12-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1445283/000107261319000310/0001072613-19-000310-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000110465919005828/0001104659-19-005828-index.htm
2019-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000113777419000026/0001137774-19-000026-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000113777420000052/0001137774-20-000052-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000113777420000053/0001137774-20-000053-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000117266120000848/0001172661-20-000848-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000117266120000863/0001172661-20-000863-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518291435/0001193125-18-291435-index.htm
2018-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518301087/0001193125-18-301087-index.htm
2018-10-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1445283/000119312518304484/0001193125-18-304484-index.htm
2018-10-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1445283/000119312518306401/0001193125-18-306401-index.htm
2018-10-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518306412/0001193125-18-306412-index.htm
2018-11-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1445283/000119312518333095/0001193125-18-333095-index.htm
2018-11-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518335843/0001193125-18-335843-index.htm
2018-11-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1445283/000119312518339620/0001193125-18-339620-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518350418/0001193125-18-350418-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312518362273/0001193125-18-362273-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519003132/0001193125-19-003132-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519028883/0001193125-19-028883-index.htm
2019-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519034125/0001193125-19-034125-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519052899/0001193125-19-052899-index.htm
2019-03-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1445283/000119312519069097/0001193125-19-069097-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519084285/0001193125-19-084285-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519091750/0001193125-19-091750-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1445283/000119312519129275/0001193125-19-129275-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1445283/000119312519129301/0001193125-19-129301-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519141587/0001193125-19-141587-index.htm
2019-05-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1445283/000119312519142280/0001193125-19-142280-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519142283/0001193125-19-142283-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519144823/0001193125-19-144823-index.htm
2019-05-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1445283/000119312519144827/0001193125-19-144827-index.htm
2019-05-138-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519145528/0001193125-19-145528-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519156984/0001193125-19-156984-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519164606/0001193125-19-164606-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519188228/0001193125-19-188228-index.htm
2019-07-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519203968/0001193125-19-203968-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519213082/0001193125-19-213082-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519215312/0001193125-19-215312-index.htm
2019-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519235279/0001193125-19-235279-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519261171/0001193125-19-261171-index.htm
2019-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519281202/0001193125-19-281202-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519287278/0001193125-19-287278-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519303727/0001193125-19-303727-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519305785/0001193125-19-305785-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519310887/0001193125-19-310887-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312519315680/0001193125-19-315680-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520006013/0001193125-20-006013-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520011454/0001193125-20-011454-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520045520/0001193125-20-045520-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520063132/0001193125-20-063132-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520068856/0001193125-20-068856-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520073083/0001193125-20-073083-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520126256/0001193125-20-126256-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1445283/000119312520126261/0001193125-20-126261-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520143981/0001193125-20-143981-index.htm
2020-06-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1445283/000119312520162178/0001193125-20-162178-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520185188/0001193125-20-185188-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520211892/0001193125-20-211892-index.htm
2020-08-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520228586/0001193125-20-228586-index.htm
2020-08-24425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520228587/0001193125-20-228587-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520248142/0001193125-20-248142-index.htm
2020-09-17425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520248143/0001193125-20-248143-index.htm
2020-09-23S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520252382/0001193125-20-252382-index.htm
2020-10-28S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520279947/0001193125-20-279947-index.htm
2020-11-06S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520288030/0001193125-20-288030-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1445283/000119312520288038/0001193125-20-288038-index.htm
2020-11-06425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1445283/000119312520288039/0001193125-20-288039-index.htm
2018-08-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919118046224/0001209191-18-046224-index.htm
2018-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919118056298/0001209191-18-056298-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119006009/0001209191-19-006009-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007568/0001209191-19-007568-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007570/0001209191-19-007570-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007572/0001209191-19-007572-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007574/0001209191-19-007574-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007576/0001209191-19-007576-index.htm
2019-02-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007617/0001209191-19-007617-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119007619/0001209191-19-007619-index.htm
2019-02-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119008082/0001209191-19-008082-index.htm
2019-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119008088/0001209191-19-008088-index.htm
2019-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119010151/0001209191-19-010151-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016537/0001209191-19-016537-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016549/0001209191-19-016549-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016570/0001209191-19-016570-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016597/0001209191-19-016597-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016607/0001209191-19-016607-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119016621/0001209191-19-016621-index.htm
2019-03-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119018093/0001209191-19-018093-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119018095/0001209191-19-018095-index.htm
2019-05-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119029707/0001209191-19-029707-index.htm
2019-05-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119029710/0001209191-19-029710-index.htm
2019-05-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119033656/0001209191-19-033656-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119039702/0001209191-19-039702-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119039703/0001209191-19-039703-index.htm
2019-11-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919119058418/0001209191-19-058418-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016213/0001209191-20-016213-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016218/0001209191-20-016218-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016226/0001209191-20-016226-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016230/0001209191-20-016230-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016234/0001209191-20-016234-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120016238/0001209191-20-016238-index.htm
2020-05-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120029750/0001209191-20-029750-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039815/0001209191-20-039815-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039822/0001209191-20-039822-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039823/0001209191-20-039823-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039825/0001209191-20-039825-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039861/0001209191-20-039861-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1445283/000120919120039868/0001209191-20-039868-index.htm
2019-03-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000121465919002154/0001214659-19-002154-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1445283/000121465920001426/0001214659-20-001426-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459018027424/0001564590-18-027424-index.htm
2019-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1445283/000156459019006999/0001564590-19-006999-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459019017332/0001564590-19-017332-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459019030053/0001564590-19-030053-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459019041718/0001564590-19-041718-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1445283/000156459020009767/0001564590-20-009767-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459020025816/0001564590-20-025816-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1445283/000156459020037724/0001564590-20-037724-index.htm
2018-12-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1445283/999999999518003044/9999999995-18-003044-index.htm
2019-05-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1445283/999999999719004514/9999999997-19-004514-index.htm

Proteostasis Therapeutics, Inc (PTI) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Proteostasis Therapeutics, Inc (PTI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1530%
Institutional Ownership: 2257%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-02-04Geoffrey S. GilmartinChief Development OfficerSell9,189.002.9927,479.7014,911.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007570/0001209191-19-007570-index.htm
2019-02-04Benito MunozChief Scientific OfficerSell9,514.002.9928,453.5215,439.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007574/0001209191-19-007574-index.htm
2019-02-04Po Shun LeeOfficerSell9,931.002.9929,699.6518,427.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007572/0001209191-19-007572-index.htm
2019-02-01Marija ZecevicChief Operating OfficerBuy22,313.0022,313.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007576/0001209191-19-007576-index.htm
2019-01-29Po Shun LeeOfficerSell712.003.002,136.002,312.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119006009/0001209191-19-006009-index.htm
2019-02-01Geoffrey S. GilmartinChief Development OfficerBuy24,100.0024,100.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007570/0001209191-19-007570-index.htm
2019-02-01Benito MunozChief Scientific OfficerBuy24,953.0024,953.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007574/0001209191-19-007574-index.htm
2019-02-01Po Shun LeeOfficerBuy26,046.0028,358.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007572/0001209191-19-007572-index.htm
2019-01-28Po Shun LeeOfficerSell1,600.003.004,800.003,024.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119006009/0001209191-19-006009-index.htm
2018-10-26FRANKLIN M BERGERDirectorBuy40,000.006.75270,000.0040,000.00https://www.sec.gov/Archives/edgar/data/1445283/000120919118056298/0001209191-18-056298-index.htm
2019-11-27New Enterprise Associates 12, Limited Partnership10% Share HolderSell1,166,755.002.522,941,739.384,270,691.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119058418/0001209191-19-058418-index.htm
2019-11-26New Enterprise Associates 12, Limited Partnership10% Share HolderSell117,164.002.45287,133.815,437,446.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119058418/0001209191-19-058418-index.htm
2019-02-04Meenu ChhabraPresident and CEOSell16,478.002.9949,305.4780,615.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007568/0001209191-19-007568-index.htm
2019-02-01Meenu ChhabraPresident and CEOBuy46,875.0097,093.00https://www.sec.gov/Archives/edgar/data/1445283/000120919119007568/0001209191-19-007568-index.htm